Vedolizumab is an integrin receptor antagonist indicated for treatment of inflammatory bowel disease. It has been studied in the treatment of immune-mediated diarrhea and colitis with favorable results in response, reduced hospitalizations and shorter steroid use duration.

View Intervention Evaluation Table